Meeting
2023 ASCO Annual Meeting
Frequency and spectrum of clinically significant molecular alterations detected by tumor gene panel testing for pediatric cancer patients in the Texas KidsCanSeq study.
Authors
Frank Y. Lin
Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX
Frank Y. Lin , Jacquelyn Reuther , Samara L Potter , Ross Mangum , Carrie A Mohila , John Hicks , Donna M. Muzny , Juan Carlos Bernini , Jonathan Benjamin Gill , Timothy Cameron Griffin , Gail Elizabeth Tomlinson , Kelly L. Vallance , Jennifer Foster , Carl E. Allen , Murali M. Chintagumpala , Dolores H. López-Terrada , Kevin Fisher , Angshumoy Roy , Sharon E. Plon , Donald Williams Parsons
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10018)
DOI
10.1200/JCO.2023.41.16_suppl.10018
Abstract #
10018
Poster Bd #
324
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2022 ASCO Annual Meeting
Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).
First Author: Camila Bragança Xavier
Poster
2020 ASCO Virtual Scientific Program
Enrichment of alterations in targetable molecular pathways in KRAS wild-type (WT) pancreatic cancer (PC).
First Author: Philip Agop Philip
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock